Rx Product News

Published Online: Friday, July 11, 2014
Follow Pharmacy_Times:

Incruse Ellipta
Marketed by: GlaxoSmithKline
Indication: The FDA has approved Incruse Ellipta (umeclidinium inhalation powder), an anticholinergic, for longterm, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Incruse Ellipta is for oral inhalation only. The inhaler contains a double-foil blister strip of powder formulation. For maintenance treatment of COPD, 1 inhalation of Incruse Ellipta once daily is recommended.
Dosage Form: Inhalation powder: umeclidinium 62.5 mcg per blister
For More Information: www.gsk.com


Otrexup
Marketed by: Antares Pharma, Inc
Indication: The FDA has approved Otrexup (methotrexate) injection to treat rheumatoid arthritis (RA) and psoriasis in adults, and polyarticular idiopathic arthritis (pJIA) in children. Otrexup is for once-weekly subcutaneous use only and should be administered in the abdomen or thigh. The starting doses are as follows: for RA, 7.5 mg once weekly; for pJIA, 10 mg/ m2 once weekly; for psoriasis, 10 to 25 mg once weekly of an oral, intramuscular, subcutaneous, or intravenous formulation.
Dosage Form: Single-dose autoinjector: 10, 15, 20, or 25 mg
For More Information: www.otrexup.com


Xartemis XR
Marketed by: Mallinckrodt Pharmaceuticals
Indication: The FDA has approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended- Release Tablets for the management of acute pain severe enough to require opioid treatment and for which alternative treatment options are inadequate. The recommended dose of Xartemis XR is 2 tablets every 12 hours without regard to food. Tablets should be swallowed whole, and complete swallowing should be ensured immediately after placing them in the mouth.
Dosage Form: Extended-release tablets (oxycodone hydrochloride/acetaminophen): 7.5 mg/325 mg
For More Information: www.xartemisxr.com


Ragwitek
Marketed by: Merck & Co, Inc
Indication: The FDA has approved Ragwitek (short ragweed pollen allergen extract) as immunotherapy for the treatment of short ragweed pollen– induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Ragwitek is approved for use in adults 18 through 65 years of age. The recommended dosage is 1 tablet daily sublingually.
Dosage Form: Tablets: 12 Amb a 1-unit
For More Information: www.ragwitek.com


Related Articles
Up to 15% of patients who receive a statin experience muscle pain, for which clinicians have only a few options: prescribing a different statin, reducing the dose of the current statin, or stopping statin therapy entirely.
A drug therapy for epilepsy and shingles pain is being voluntarily recalled by its manufacturer due to complaints of empty capsules.
A study from Bristol-Myers Squibb shows a combination of abatacept and methotrexate could help slow the disease progression of rheumatoid arthritis.
A diverse collective of health care advocacy groups, patient organizations, industry representatives and other stakeholders today announced they have established the Alliance for Balanced Pain Management to support appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to reduce abuse. AfBPM will work collaboratively to educate, support and advocate on behalf of people affected by pain, both acute and chronic.
Latest Issues
$auto_registration$